Xian Zheng | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Dr. Xian Zheng | Pharmaceutical Science | Best Researcher Award

Assistant research Fellow of Affiliated Kunshan Hospital of Jiangsu University, China.

Xian Zheng is a prominent researcher specializing in Chinese herbal drugs, natural products, and nonalcoholic fatty liver disease (NAFLD). With a Ph.D. in Chinese pharmacy from China Pharmaceutical University, he currently serves as an Assistant Researcher at the Affiliated Kunshan Hospital of Jiangsu University and a part-time postdoctoral researcher at the Suzhou Institute of Nano-tech and Nano-bionics. Zheng leads several high-impact projects, including studies on arjunolic acid and liposome-based therapies for NAFLD, supported by major funding bodies like the National Natural Science Foundation of China. His research is well-regarded, with numerous publications in leading journals such as Phytomedicine and J Functional Foods. Zheng has been honored with awards like Jiangsu Double Innovation Doctor and Gusu Health Talents Plan-“Class D special talents”. His work showcases significant contributions to the field, marked by a strong publication record and leadership in innovative research.

Profile
Education

Xian Zheng’s educational background reflects a strong foundation in pharmacology and pharmacy. He earned his Ph.D. in Chinese Pharmacy from the College of Traditional Chinese Medicine at China Pharmaceutical University, Nanjing, in December 2021, under the supervision of Professor Zhiqi Yin. Prior to this, he completed his Master of Science in Pharmacology at the School of Pharmacy, Xuzhou Medical University, in June 2018, guided by Professor Yi Liu. Zheng’s academic journey began with a Ph.D. in Pharmacy from the School of Pharmacy, Nanjing2 University of Chinese Medicine, which he completed in June 2015. This extensive education, encompassing both traditional Chinese medicine and modern pharmacology, has provided him with a robust understanding of drug development and therapeutic applications, particularly in the realm of natural products and their effects on nonalcoholic fatty liver disease.

Professional Experience

Xian Zheng currently serves as an Assistant Researcher at the Department of Pharmacy, Affiliated Kunshan Hospital of Jiangsu University, where he has been contributing to cutting-edge research since February 2022. Additionally, he is a part-time postdoctoral researcher at the Suzhou Institute of Nano-tech and Nano-bionics, a position he has held since October 2022. Zheng’s professional journey includes significant achievements in studying Chinese herbal drugs and natural products, particularly in the context of nonalcoholic fatty liver disease (NAFLD). He leads multiple high-profile research projects funded by prestigious organizations such as the National Natural Science Foundation of China and the Gusu Health Talent Research Project. His expertise in pharmacology and his leadership in these research initiatives highlight his dedication and impact in advancing therapeutic strategies for NAFLD and related conditions.

Research Interest

Xian Zheng’s research interests primarily focus on Chinese herbal drugs and natural products, with a particular emphasis on their therapeutic potential for nonalcoholic fatty liver disease (NAFLD). His work explores innovative treatment approaches, such as the dual NAMPT activation theory, and the development of liposome-based drug delivery systems to enhance the efficacy of herbal compounds. Zheng’s research aims to uncover the underlying mechanisms of these treatments, such as their effects on metabolic pathways and cellular functions. He is dedicated to advancing the understanding of how traditional herbal remedies can be optimized and integrated into modern therapeutic strategies for complex liver diseases. By combining traditional pharmacological insights with contemporary biomedical techniques, Zheng seeks to bridge the gap between ancient remedies and modern medicine, ultimately improving clinical outcomes for patients with NAFLD and contributing to the broader field of natural product research.

Research Skills

Xian Zheng demonstrates exceptional research skills, particularly in the domain of pharmacology and natural product research. His expertise encompasses a comprehensive understanding of Chinese herbal drugs and their therapeutic applications, with a specific focus on nonalcoholic fatty liver disease (NAFLD). Zheng excels in designing and leading innovative research projects, such as exploring dual NAMPT activation and developing liposome-based therapies for NAFLD. His ability to secure funding from prestigious organizations, including the National Natural Science Foundation of China, underscores his proficiency in research proposal development and project management. Zheng’s analytical skills are evident in his extensive publication record in reputable journals, where he contributes to advancing knowledge in his field. His role as a part-time postdoctoral researcher further reflects his commitment to scientific inquiry and collaboration. Overall, Zheng’s research skills are marked by a blend of innovative thinking, effective project leadership, and a strong publication track record.

Awards and Recognition

Xian Zheng has earned notable recognition in his field through a series of prestigious awards and honors. His achievements include being named a Jiangsu Double Innovation Doctor, which acknowledges his exceptional contributions to innovative research in Chinese pharmacy. Additionally, Zheng is distinguished as a “Class D special talents” under the Gusu Health Talents Plan, underscoring his impactful work in the realm of natural products and nonalcoholic fatty liver disease. He was also recognized as a Kunshan Youth Post Expert in 2022 and a Suzhou Youth Post Expert in 2023, highlighting his significant contributions to the scientific community and his leadership in advancing research. These accolades reflect Zheng’s dedication and impact in the field of pharmacology and his commitment to advancing therapeutic approaches through his innovative research efforts.

Conclusion

Dr. Tao Song is a strong candidate for the Best Researcher Award due to his significant contributions to the field of catalysis and green chemistry. His innovative research and high-impact publications demonstrate a clear potential for future leadership in the field. To further strengthen his candidacy, Dr. Song could focus on expanding the impact of his research through interdisciplinary collaborations and leadership roles. Given his achievements and potential, Dr. Song is well-suited for recognition as a leading researcher in his field.

Publications Top Notes

  1. Arjunolic Acid from Cyclocarya paliurus Selectively Inhibits Glucagon Secretion from α Cells and Ameliorates Diabetes via Ephrin-A1 and EphA4 Interaction
    • Authors: Fang, C.-Q., Teng, Y., Wang, Y.-T., Cao, X.-L., Jiang, C.-H.
    • Year: 2022
  2. Aloin A Prevents Ulcerative Colitis in Mice by Enhancing the Intestinal Barrier Function via Suppressing the Notch Signaling Pathway
    • Authors: Jiang, H., Shi, G.-F., Fang, Y.-X., Zhang, J., Yin, Z.-Q.
    • Year: 2022
    • Citations: 11
  3. Protective Effects of Cyclocarya paliurus on Hyperuricemia and Urate-Induced Inflammation
    • Authors: Zhu, L.-H., Xu, Y.-Y., Zhu, L.-P., Zhang, J., Yin, Z.-Q.
    • Year: 2022
    • Citations: 9
  4. Cyclocarya paliurus Triterpenoids Attenuate Glomerular Endothelial Injury in Diabetic Rats via ROCK Pathway
    • Authors: Yang, R., Xu, S., Zhang, X., Yin, Z., Pan, K.
    • Year: 2022
    • Citations: 8
  5. Chrysin Inhibits Hepatocellular Carcinoma Progression Through Suppressing Programmed Death Ligand 1 Expression
    • Authors: Rong, W., Wan, N., Zheng, X., Gao, Z.-J., Zhang, J.
    • Year: 2022
    • Citations: 17
  6. New Dammarane-Type Triterpenoid Saponins from Gynostemma pentaphyllum and Their Sirt1 Agonist Activity
    • Authors: Lou, Y.-Y., Zheng, X., Huang, Y.-P., Yin, Z.-Q., Pan, K.
    • Year: 2021
    • Citations: 12
  7. Arjunolic Acid from Cyclocarya paliurus Ameliorates Nonalcoholic Fatty Liver Disease in Mice via Activating Sirt1/AMPK, Triggering Autophagy and Improving Gut Barrier Function
    • Authors: Zheng, X., Zhang, X.-G., Liu, Y., Zhang, J., Yin, Z.-Q.
    • Year: 2021
    • Citations: 6
  8. Aloe Vera Mitigates Dextran Sulfate Sodium-Induced Rat Ulcerative Colitis by Potentiating Colon Mucus Barrier
    • Authors: Shi, G., Jiang, H., Feng, J., Jiang, C., Zhang, J.
    • Year: 2021
    • Citations: 30
  9. Four New Dammarane Triterpenoid Glycosides from the Leaves of Cyclocarya paliurus and Their SIRT1 Activation Activities
    • Authors: Zhu, L.-P., Yang, H.-M., Zheng, X., Zhang, J., Yin, Z.-Q.
    • Year: 2021
    • Citations: 7
  10. Gypenoside LVI Improves Hepatic LDL Uptake by Decreasing PCSK9 and Upregulating LDLR Expression
    • Authors: Wang, J., Wang, Y.-S., Huang, Y.-P., Yin, Z.-Q., Zhang, J.
    • Year: 2021
    • Citations: 21

 

Justine Benevent | Pharmaceutical Science | Best Scholar Award

Posted on by ScienceFather

Dr. Justine Benevent | Pharmaceutical Science | Best Scholar Award

MCU-PH at CHU Toulouse, INSERM CERPOP, France

Based on the provided information, Justine Benevent appears to be a strong candidate for the Best Scholar Award. Here is a detailed assessment of her suitability, structured by various criteria:

Education

Justine Benevent’s educational background is distinguished by a series of advanced degrees in pharmacology and related fields. She holds a Diplôme d’état de Docteur en Pharmacie from Bordeaux, providing a comprehensive foundation in pharmacy. She further specialized with a DESC de Pharmacologie médicale from Bordeaux, focusing on medical pharmacology. Her academic journey continued with a Thèse d’Université de Pharmacologie in Toulouse, where she engaged in in-depth research. She also earned a Diplôme Universitaire de pédagogie en Santé from Toulouse, enhancing her skills in health education. Additionally, she completed the DES Pharmacie hospitalière from Bordeaux, highlighting her expertise in hospital pharmacy. These qualifications reflect her extensive training and dedication to the field of pharmacology, underpinning her expertise and contributions to research and clinical practice.

Research Contributions

Justine Benevent has made significant research contributions in pharmacology, with a focus on medications, reproduction, pregnancy, and breastfeeding. She has a solid publication record with 33 papers, including 6 as the first author, and a notable h-index of 10, indicating her research impact and recognition in the academic community.

Geographic Impact

Her research has a wide geographic impact, involving collaborations with international institutions such as PharmaSafe at the University of Oslo, Norway. Her work with the European Consortium IMI ConcePTION highlights her ability to engage in research that transcends national boundaries, addressing health issues relevant to diverse populations.

Collaborative Efforts

Justine Benevent is actively involved in several collaborative research projects and networks. She is a partner of the European Consortium IMI ConcePTION, a member of the national network REGARDs, and participates in various working groups, including those focused on mental health and reproductive risks of drugs. These collaborations demonstrate her commitment to multi-disciplinary and international research efforts.

Applied Research

Her research is highly applied, focusing on real-world health issues such as the effects of medications during pregnancy and breastfeeding. Her role in the project “Maison des Femmes” at CHU de Toulouse, aimed at improving healthcare for women, underscores her dedication to applying research findings to enhance community health and well-being.

Specific Projects and Publications

Justine Benevent has led and contributed to numerous impactful projects. Her work within the “Santé périnatale, pédiatrique et des adolescents” team at CERPOP addresses critical aspects of perinatal and pediatric health. She has also been involved in leading two projects within the IMI ConcePTION consortium, further highlighting her leadership in significant research initiatives.

Environmental Health

While her primary focus is on pharmacology and reproductive health, her work indirectly impacts environmental health by addressing the safe use of medications during critical periods such as pregnancy and breastfeeding. This contributes to overall community health by ensuring safer pharmaceutical practices.

Vector Control

There is no direct mention of research in vector control in her profile. However, her extensive work in pharmacology and drug safety may intersect with public health strategies that could include elements of vector control indirectly.

Waste Management and Water Quality

Justine Benevent’s profile does not indicate direct involvement in waste management and water quality research. Her expertise lies primarily in pharmacology and clinical research methodology.

Parasitology and Infectious Diseases

Although parasitology and infectious diseases are not explicitly mentioned, her pharmacological research, especially in the context of reproductive health, could contribute to understanding and managing infections that affect pregnant women and infants.

Awards and Recognition

Justine Benevent’s academic and research achievements have been recognized through various positions and memberships, such as her role as Treasurer of the CNPM (Collège National de Pharmacologie Médicale) and her involvement in the French Society of Pharmacology and Therapeutics (SFPT). Her significant publication record and citation count further attest to her recognition in the field.

Conclusion

Justine Benevent is a highly accomplished scholar with a strong background in pharmacology, evidenced by her extensive research contributions, collaborative efforts, and applied research impact. Her work addresses crucial health issues related to medications and reproductive health, making her a deserving candidate for the Best Scholar Award. Her leadership in various national and international research projects and her dedication to improving community health through applied research are particularly commendable.

Publications Top Notes

  1. Teaching pharmacovigilance to French medical students during the COVID-19 pandemic: Interest of distance learning clinical reasoning sessions
    • Authors: F. Montastruc, F. Muscari, I. Tack, G. Durrieu, A. Sommet
    • Year: 2024
  2. Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: A systematic review and meta-analysis
    • Authors: L. Saint-Lary, J. Benevent, C. Damase-Michel, V. Leroy, A. Sommet
    • Year: 2023
    • Citations: 2
  3. Drug monitoring in pregnant women: about the Regards network | Surveillance des médicaments chez les femmes enceintes : à propos du réseau Regards
    • Authors: I. Lacroix, M. Araujo, A. Caillet, L. Delteil, C. Damase-Michel
    • Year: 2023
    • Citations: 1
  4. Risk of Hypertensive Disorders of Pregnancy in Women Treated With Serotonin-Norepinephrine Reuptake Inhibitors: A Comparative Study Using the EFEMERIS Database
    • Authors: J. Benevent, M. Araujo, S. Karki, S. Tebeka, C. Damase-Michel
    • Year: 2023
    • Citations: 2
  5. Adverse drug reactions in pregnant women: Do they differ from those in non-pregnant women of childbearing age?
    • Authors: M. Balon, S. Tessier, C. Damase-Michel, J. Benevent, I. Lacroix
    • Year: 2023
    • Citations: 5
  6. First trimester pregnancy exposure to fosfomycin and risk of major congenital anomaly: a comparative study in the EFEMERIS database
    • Authors: J. Benevent, M. Araujo, A.-B. Beau, I. Lacroix, C. Damase-Michel
    • Year: 2023
    • Citations: 3
  7. Interactions between antiseizure medications and contraception: A study about the knowledge of patients and their specialist physicians
    • Authors: A. Gosset, M. Denuelle, L. Valton, B.énévent, F. Tremollières
    • Year: 2022
    • Citations: 5
  8. Prenatal Drug Exposure in Children With a History of Neuropsychiatric Care: A Nested Case-Control Study
    • Authors: J. Benevent, C. Hurault-Delarue, M. Araujo, I. Lacroix, C. Damase-Michel
    • Year: 2022
  9. What changes in prescription patterns of antiemetic medications in pregnant women in France?
    • Authors: C. Hurault-Delarue, M. Araujo, C. Vabre, C. Damase-Michel, I. Lacroix
    • Year: 2021
    • Citations: 4
  10. Maternal Medication Use and Childhood Cancer in Offspring-Systematic Review and Considerations for Researchers
    • Authors: S. Hjorth, C.H. Hemmingsen, J. Benevent, M. Hargreave, H. Nordeng
    • Year: 2021
    • Citations: 2